Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (stock code: 02675.HK) officially listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic surgical robotics in China [2] Group 1: IPO and Financials - The company raised approximately HKD 1.2 billion by issuing 27.72 million shares at an offering price of HKD 43.24 per share, resulting in a post-IPO market capitalization of around HKD 16.8 billion, which increased to approximately HKD 21.9 billion (about RMB 19.6 billion) at the time of reporting [2] - The IPO attracted 13 cornerstone investors, including major institutions like Abu Dhabi Investment Authority (ADIA) and Tencent, collectively subscribing for USD 75 million, accounting for 48.7% of the total fundraising [3] - Prior to the IPO, the company completed 8 rounds of financing, raising over RMB 2 billion, with a valuation increase from RMB 43 million in early stages to nearly RMB 15 billion before the IPO [4] Group 2: Founders and Company Background - The founders, Wang Jianchen and Gao Yuanqian, both PhD graduates born in the 1980s, transformed a startup into a leading player in the global surgical robotics field within 9 years [2][5] - The company focuses on developing high-end surgical robots, specifically targeting the challenging area of single-port surgical robots, which minimize trauma and improve recovery times [8][10] Group 3: Product Development and Market Position - Precision Medical has developed a complete product line covering multi-port, single-port, and natural orifice surgical robots, becoming the second company globally to achieve this [11] - The company’s products are designed to meet the needs of Chinese medical practices, with 100% self-research and 85% localized supply chains, making them 60-70% cheaper than imported brands [14] - The company has achieved significant clinical milestones, including the successful completion of over 14,000 assisted surgeries and the establishment of a clinical support system to ensure effective use of its products [17][19] Group 4: Market Trends and Future Outlook - The global surgical robotics market is projected to grow from USD 21.2 billion in 2024 to USD 84.2 billion by 2033, with a compound annual growth rate (CAGR) of 16.6%, while the Chinese market is expected to grow at a much faster rate of 34.3% [21][22] - The penetration rate of laparoscopic surgical robots in China is currently low at approximately 0.7%, indicating a significant opportunity for growth as domestic brands capture nearly 50% of the market share [22] - The competitive landscape is intensifying, with major players like Intuitive Surgical and Precision Medical leading the market, and the focus shifting from mere existence to product quality and operational efficiency [22][23]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as "Precision Medical") is the first company in China and the second globally to commercialize both multi-port and single-port surgical robots, marking a significant milestone in the surgical robotics industry [2][4]. Group 1: IPO Details - Precision Medical officially listed on the Hong Kong Stock Exchange on January 8, 2026, under the stock code "2675" [2]. - The company issued a total of 27,722,200 H shares, with the Hong Kong public offering being oversubscribed by 1,091.94 times and the international offering by 25.18 times [2]. - The IPO raised approximately HKD 1.199 billion at an issue price of HKD 43.24 per share, with the stock opening at HKD 59, giving it a market capitalization exceeding HKD 22.8 billion [2]. Group 2: Technological Innovation - Precision Medical focuses on the independent research and development of high-end minimally invasive surgical equipment, aiming to upgrade surgical procedures towards precision, minimally invasive, and intelligent solutions [4]. - The company has developed a comprehensive product lineup covering multi-port, single-port, and natural orifice surgical robots, achieving autonomy in several key technological areas [4]. - As of now, Precision Medical holds 734 authorized and pending patents globally, establishing a robust technical system that encompasses research and development, manufacturing, clinical application, and continuous iteration [4]. Group 3: Clinical Application and Growth - Over 12,000 surgeries have been performed using the multi-port surgical robot, and more than 2,000 surgeries with the single-port robot, indicating a stable growth in clinical usage and integration into standard surgical pathways [5]. - The company reported approximately CNY 149 million in revenue for the first half of 2025, representing a nearly 400% year-on-year increase, with a gross margin of about 62.8% [4][5]. - Precision Medical plans to leverage its IPO as a new starting point to enhance research and development in advanced technologies, complex procedures, and remote surgeries, while expanding production capacity and global market reach [5]. Group 4: Market Position and Future Outlook - Investors such as Qiming Venture Partners and Sequoia China view Precision Medical's successful IPO as a landmark achievement in breaking international monopolies and leading the development of China's surgical robotics industry [6][7]. - The company is expected to continue expanding its clinical applications and global market presence, contributing significantly to the high-quality development of China's high-end medical equipment industry [6][7]. - Precision Medical is recognized for its rapid product iteration and strong market acceptance, positioning itself as a leading player in the surgical robotics sector both domestically and internationally [6][7].